Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States.
作者信息
Patell Rushad, Midha Shonali, Kimani Stephen, Martin Richard, Neparidze Natalia, Jaglal Michael, Freed Jason, Key Nigel S
机构信息
Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.
H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, Florida, United States.
出版信息
Thromb Haemost. 2020 Dec;120(12):1725-1732. doi: 10.1055/s-0040-1715837. Epub 2020 Aug 22.
Abstract
摘要
相似文献
1
Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States.美国 COVID-19 相关凝血病机构指南的差异
Thromb Haemost. 2020 Dec;120(12):1725-1732. doi: 10.1055/s-0040-1715837. Epub 2020 Aug 22.
2
COVID-19 update: Covid-19-associated coagulopathy.新型冠状病毒肺炎最新情况：新型冠状病毒肺炎相关凝血病
J Thromb Thrombolysis. 2020 Jul;50(1):54-67. doi: 10.1007/s11239-020-02134-3.
3
Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19.新型冠状病毒肺炎患者的凝血病、静脉血栓栓塞和抗凝治疗。
Pharmacotherapy. 2020 Nov;40(11):1130-1151. doi: 10.1002/phar.2465. Epub 2020 Nov 3.
4
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.住院 COVID-19 患者的凝血病：治疗性抗凝与标准治疗作为对 COVID-19 大流行的快速反应的实用随机对照试验 (RAPID COVID COAG - RAPID 试验)：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Mar 10;22(1):202. doi: 10.1186/s13063-021-05076-0.
5
A Ghana-UK haematology "heparin" partnership.加纳与英国血液学领域的“肝素”合作关系。
Br J Haematol. 2020 Nov;191(3):e96-e97. doi: 10.1111/bjh.17048. Epub 2020 Aug 15.
6
Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?新冠病毒相关凝血病的多因素发病机制：去纤苷在凝血障碍早期阶段能发挥作用吗？
J Thromb Haemost. 2020 Nov;18(11):3106-3108. doi: 10.1111/jth.15021.
7
Transfusion requirements in patients with COVID-19.新型冠状病毒肺炎患者的输血需求
Eur J Haematol. 2021 Jan;106(1):132-134. doi: 10.1111/ejh.13521. Epub 2020 Oct 9.
8
COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year.COVID-19 相关凝血功能障碍与抗血栓药物——1 年后的经验教训。
Lancet Haematol. 2021 Jul;8(7):e524-e533. doi: 10.1016/S2352-3026(21)00105-8. Epub 2021 Apr 27.
9
Coagulation abnormalities & thromboprophylaxis in COVID-19.新型冠状病毒肺炎的凝血异常与血栓预防。
Indian J Med Res. 2021;153(5&6):606-618. doi: 10.4103/ijmr.IJMR_3841_20.
10
Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?疫情爆发四年后，如何管理患有急性凝血病的新冠患者：我们学到了什么？
J Thromb Haemost. 2024 Jun;22(6):1541-1549. doi: 10.1016/j.jtha.2024.02.013. Epub 2024 Feb 29.
引用本文的文献
1
National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19.国家结核病和肺部疾病研究所（NRITLD）新冠病毒病患者治疗方案
Iran J Pharm Res. 2022 Mar 30;21(1):e123947. doi: 10.5812/ijpr.123947. eCollection 2022 Dec.
2
Thromboprophylaxis in COVID-19: Weight and severity adjusted intensified dosing.2019冠状病毒病的血栓预防：根据体重和严重程度调整强化剂量。
Res Pract Thromb Haemost. 2022 Apr 5;6(3):e12683. doi: 10.1002/rth2.12683. eCollection 2022 Mar.
3
Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study.通过大型学术医疗系统中的临床决策支持系统实施COVID-19抗凝治疗实践指南及其评估：观察性研究
JMIR Med Inform. 2021 Nov 18;9(11):e30743. doi: 10.2196/30743.
4
Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform.组建血液肿瘤协作视频会议（CO-VID）学习计划：从新型以学员为主体的多学科虚拟学习平台中获得的经验教训。
JCO Oncol Pract. 2022 Jan;18(1):e36-e46. doi: 10.1200/OP.20.00960. Epub 2021 Jul 9.
5
The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper.《COVID-19 大流行与采取综合公平方法的必要性：国际专家共识文件》。
Thromb Haemost. 2021 Aug;121(8):992-1007. doi: 10.1055/a-1535-8807. Epub 2021 Jul 20.
6
Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis.COVID-19 住院患者的药物性血栓预防和血栓形成：汇总分析。
Thromb Haemost. 2021 Jan;121(1):76-85. doi: 10.1055/s-0040-1721664. Epub 2020 Dec 30.
7
Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.新型冠状病毒病病理生理学中的炎症与血栓形成：蛋白水解酶激活和嘌呤能受体作为驱动因素和候选治疗靶点。
Physiol Rev. 2021 Apr 1;101(2):545-567. doi: 10.1152/physrev.00035.2020. Epub 2020 Oct 30.
本文引用的文献
1
Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology.2019冠状病毒病大流行期间抗栓治疗的建议。西班牙心脏病学会心血管血栓形成工作组立场声明
Rev Esp Cardiol (Engl Ed). 2020 Sep;73(9):749-757. doi: 10.1016/j.rec.2020.04.025. Epub 2020 Jun 19.
2
Emergence of institutional antithrombotic protocols for coronavirus 2019.2019冠状病毒病机构性抗血栓形成方案的出现。
Res Pract Thromb Haemost. 2020 Jun 12;4(4):510-517. doi: 10.1002/rth2.12358. eCollection 2020 May.
3
Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathy-Either, Neither, or Both.2019冠状病毒病凝血障碍：弥散性血管内凝血和血栓性微血管病——是其一、均不是或两者皆是。
Semin Thromb Hemost. 2020 Oct;46(7):781-784. doi: 10.1055/s-0040-1712156. Epub 2020 Jun 8.
4
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.针对 COVID-19 的血栓炎症的药物靶点：综述及对未来研究的启示。
Thromb Haemost. 2020 Jul;120(7):1004-1024. doi: 10.1055/s-0040-1713152. Epub 2020 May 30.
5
Coagulation abnormalities and thrombosis in patients with COVID-19.新型冠状病毒肺炎患者的凝血异常与血栓形成
Lancet Haematol. 2020 Jun;7(6):e438-e440. doi: 10.1016/S2352-3026(20)30145-9. Epub 2020 May 11.
6
Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels.COVID-19 肺炎伴 D-二聚体升高患者无症状性深静脉血栓形成的发生率。
Thromb Res. 2020 Aug;192:23-26. doi: 10.1016/j.thromres.2020.05.018. Epub 2020 May 13.
7
Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.确认 COVID-19 重症 ICU 患者的血栓并发症累积发生率较高：更新分析。
Thromb Res. 2020 Jul;191:148-150. doi: 10.1016/j.thromres.2020.04.041. Epub 2020 Apr 30.
8
COVID-19: towards understanding of pathogenesis.新型冠状病毒肺炎：对发病机制的认识
Cell Res. 2020 May;30(5):367-369. doi: 10.1038/s41422-020-0327-4.
9
Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young.大血管卒中作为年轻人新冠病毒病的首发特征
N Engl J Med. 2020 May 14;382(20):e60. doi: 10.1056/NEJMc2009787. Epub 2020 Apr 28.
10
COVID-19 and its implications for thrombosis and anticoagulation.新型冠状病毒肺炎及其对血栓形成和抗凝的影响。
Blood. 2020 Jun 4;135(23):2033-2040. doi: 10.1182/blood.2020006000.
Zotero 插件